CSO Bill Lundberg transitions to advisor role at CRISPR Therapeutics; Prothena loses CMO Sarah Noonberg; Sanofi … – Endpoints News
Endpoints News |
CSO Bill Lundberg transitions to advisor role at CRISPR Therapeutics; Prothena loses CMO Sarah Noonberg; Sanofi …
Endpoints News Wrapping a three-year run marked by the first clinical trial applications for CRISPR-based therapies, Bill Lundberg is stepping down as CSO of CRISPR Therapeutics $CRSP. He will stay with the company as the head of its scientific advisory board. This … |
